AVXT Stock Overview
A development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
AVAX Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.00001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 900.00% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -98.00% |
| 5 Year Change | -99.17% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| AVXT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 0.5% |
| 1Y | n/a | 15.6% | 30.7% |
Return vs Industry: Insufficient data to determine how AVXT performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how AVXT performed against the US Market.
Price Volatility
| AVXT volatility | |
|---|---|
| AVXT Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AVXT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine AVXT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | n/a | www.avax-tech.com |
AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company’s product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer.
AVAX Technologies, Inc. Fundamentals Summary
| AVXT fundamental statistics | |
|---|---|
| Market cap | US$6.89k |
| Earnings (TTM) | -US$11.99m |
| Revenue (TTM) | US$142.50k |
0.0x
P/S Ratio0.0x
P/E RatioIs AVXT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVXT income statement (TTM) | |
|---|---|
| Revenue | US$142.50k |
| Cost of Revenue | US$0 |
| Gross Profit | US$142.50k |
| Other Expenses | US$12.14m |
| Earnings | -US$11.99m |
Last Reported Earnings
Dec 31, 2010
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did AVXT perform over the long term?
See historical performance and comparison